REGISTER
Roche Flu Drug Wins New Indication in China
Roche announced that baloxavir marboxil has expanded approval in China to younger children, with the dry suspension approved for uncomplicated influenza in patients aged 1 to under 5 years and tablets approved for uncomplicated influenza in adults and children aged 5 years and older.

On March 6, Roche announced that baloxavir marboxil dry suspension officially received approval from the NMPA on March 3 for an expanded indication, for the treatment of uncomplicated influenza A and B in children aged 1 year to under 5 years, including previously healthy patients and those at high risk of influenza complications.

In addition, on February 13, baloxavir marboxil tablets were formally approved by the NMPA for adults and children aged 5 years and older with uncomplicated influenza A and B, including previously healthy patients and those at high risk of influenza-related complications.

Approval of these two new indications expands the treatment age range of baloxavir marboxil from the previous 5 years and older to 1 year and older, achieving comprehensive coverage for toddlers, children, and adults.

Baloxavir marboxil is an innovative cap-dependent endonuclease inhibitor that has shown activity against multiple influenza viruses, including oseltamivir-resistant strains and avian influenza viruses such as H7N9 and H5N1 in nonclinical studies. A full course requires only a single oral dose, enabling significant reduction of viral shedding within 24 hours, shortening the infectious period, and markedly reducing the duration of influenza symptoms.

Baloxavir marboxil is the world’s first single-dose oral drug for influenza treatment and was first approved in China in April 2021. The dry suspension formulation was specially developed for children and features a strawberry flavor and precise weight-based dosing, further providing a more child-friendly influenza treatment experience for children with lower body weight or difficulty swallowing tablets.

At present, baloxavir marboxil has been approved for the treatment of influenza A and B in more than 70 countries.

0
0
Loading